rosiglitazone has been researched along with Alzheimer Disease in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (41.86) | 29.6817 |
| 2010's | 21 (48.84) | 24.3611 |
| 2020's | 4 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Chitkara, D; K C, S; Kakoty, V; Marathe, S; Taliyan, R | 1 |
| Cortez, I; Dineley, KT; Hernandez, CM | 1 |
| Hall, J; Johnson, L; O'Bryant, SE; Petersen, M; Rissman, RA; Zhang, F | 1 |
| Chitkara, D; Dubey, SK; K C, S; Kakoty, V; Krishna, KV; Taliyan, R | 1 |
| Chesson, BC; Cortez, I; Denner, L; Dineley, KT; Folorunso, O; Franklin, WF; Haidacher, SJ; Hsu, WJ; Laezza, F; Lichti, CF; Nenov, MN; Rudra, JS; Sadygov, RG; Singh, AK; Taglialatela, G; Wildburger, NC | 1 |
| Cao, L; Ji, L; Li, H; Mao, K; Sha, L; Tang, X; Wei, J; Wei, N; Wu, J; Xie, W; Yang, S; Yang, Z; Zhu, L | 1 |
| Craig, A; Issberner, J; Parvez, F | 1 |
| Dang, HZ; Li, RS; Ren, Y; Sun, HY; Wang, H; Wang, PW; Yang, JD | 1 |
| Chen, XP; Li, RS; Ren, Y; Sun, HY; Wang, H; Wang, PW; Yang, JD | 1 |
| Denner, L; Dineley, KT; Hernandez, CM; Jahrling, JB | 1 |
| Blanchard, J; Gong, CX; Iqbal, K; Li, X; Li, Y; Liu, F; Yu, Y | 1 |
| Deng, YQ; Jin, DC; Song, JZ; Sun, J | 1 |
| Jia, JP; Liu, J; Wang, LN | 1 |
| Denner, L; Dineley, KT; Laezza, F; Nenov, MN; Tempia, F | 1 |
| Cheng, H; Jiang, L; Shang, Y; Shi, TL; Wang, L | 1 |
| Bains, C; Barrett, SJ; Hosford, D; Irizarry, MC; Lai, RY; Laroche, JP; Maher-Edwards, G; Webb, DJ; Weil, JG | 1 |
| Akuffo, EL; Cutler, P; Davis, JB; Fox, SM; Gloger, IS; Hosford, D; Jones, NA; Kinsey, EE; Nock, CM; Roses, AD; Saunders, AM; Skehel, JM; Smith, MA | 1 |
| Roses, AD | 1 |
| Hayden, EC | 1 |
| Del Río, J; Escribano, L; Frechilla, D; Pérez-Mediavilla, A; Salazar-Colocho, P; Simón, AM | 1 |
| Bomfim, TR; De Felice, FG; Decker, H; Ferreira, ST; Klein, WL; Lambert, MP; Velasco, PT; Vieira, MN; Viola, KL; Zhao, WQ | 1 |
| Kamal, MA; Qu, X; Seale, JP; Tan, Y | 1 |
| Inestrosa, NC; Toledo, EM | 1 |
| Castillo-Quan, JI | 1 |
| Cuadrado-Tejedor, M; Del Río, J; Escribano, L; Frechilla, D; García-Osta, A; Gimeno, E; López de Maturana, R; Pérez-Mediavilla, A; Ricobaraza, A; Simón, AM | 1 |
| Denner, L; Dineley, KT; Rodriguez-Rivera, J | 1 |
| Alderton, C; Craft, S; Egginton, S; Gold, M; Irizarry, M; Landreth, G; Linnamägi, U; Saunders, AM; Sawchak, S; Zvartau-Hind, M | 1 |
| Bandy, D; Bird, NP; Brown, AP; Castiglia, M; Chen, K; Cunningham, VJ; Dixon, IJ; Gold, M; Hallett, WA; Jeter, B; Lai, RY; Lotay, N; Matthews, JC; Matthews, PM; Mistry, P; Nichols, TE; Rabiner, EA; Reiman, EM; Searle, G; Tzimopoulou, S; Whitcher, B; Zvartau-Hind, M | 1 |
| Chiang, C; Davies, J; Donovan, C; Gold, M; Harrington, C; Irizarry, M; Jeter, B; Saunders, AM; Sawchak, S; van Dyck, CH; Zvartau-Hind, M | 1 |
| Lynch, M; O'Reilly, JA | 1 |
| Desilets, AR; Miller, BW; Willett, KC | 1 |
| Domínguez, RO; González, SE; Marschoff, ER; Repetto, MG; Serra, JA | 1 |
| Ikeuchi, T; Kasuga, K; Nishizawa, M; Sekine, Y; Tezuka, T; Tokutake, T; Yajima, R | 1 |
| Craft, S; Watson, GS | 1 |
| Burton, A | 1 |
| Flynn, ER; Pedersen, WA | 1 |
| Asthana, S; Baker, LD; Cholerton, BA; Cook, DG; Craft, S; Fishel, MA; Green, PS; Kahn, SE; Keeling, ML; Kulstad, JJ; Plymate, SR; Reger, MA; Watson, GS | 1 |
| Craft, S; Haynatzki, GR; Kulstad, JJ; Leverenz, JB; McMillan, PJ; Pedersen, WA | 1 |
| Landreth, G | 1 |
| Huang, Y; Mahley, RW; Roses, AD; Saunders, AM; Strum, J; Weisgraber, KH | 1 |
| Ghosh, S; Mattie, M; Nock, C; Richardson, J; Roses, A; Saunders, A; Selley, P; Shehee, R; Strum, JC; Virley, D | 1 |
| Mendez, MF | 1 |
| Becker, RE; Giacobini, E | 1 |
10 review(s) available for rosiglitazone and Alzheimer Disease
| Article | Year |
|---|---|
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Insulin; Insulin Resistance; Metformin; Mice; Mice, Transgenic; Phosphorylation; Pioglitazone; Rosiglitazone; tau Proteins | 2019 |
Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cognitive Dysfunction; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2015 |
The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
Topics: Alzheimer Disease; Benzimidazoles; Benzoates; Humans; Pioglitazone; PPAR gamma; Rosiglitazone; Telmisartan; Thiazolidinediones | 2016 |
The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Biomarkers, Pharmacological; Clinical Trials as Topic; Cost-Benefit Analysis; Dideoxynucleosides; Drug Discovery; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Genome-Wide Association Study; Genotype; HLA-B Antigens; Humans; Models, Biological; Pharmacogenetics; Rosiglitazone; Sample Size; Thiazolidinediones | 2009 |
Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2011 |
The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Humans; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Topics: Alzheimer Disease; Apolipoproteins E; Biomarkers; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Genome, Human; Genotype; Humans; Pharmacogenetics; Rosiglitazone; Thiazolidinediones | 2007 |
Impaired knowledge for fruits and vegetables in semantic dementia.
Topics: Alzheimer Disease; Humans; Hypoglycemic Agents; Interleukin-6; Rosiglitazone; Thiazolidinediones | 2007 |
One hundred years after the discovery of Alzheimer's disease. A turning point for therapy?
Topics: Aged; Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Cholinesterase Inhibitors; Humans; Nerve Growth Factor; Neurofibrillary Tangles; Phosphorylation; Rosiglitazone; tau Proteins; Thiazolidinediones; Vasodilator Agents | 2007 |
7 trial(s) available for rosiglitazone and Alzheimer Disease
| Article | Year |
|---|---|
A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials.
Topics: Alzheimer Disease; Humans; Hypoglycemic Agents; PPAR gamma; Precision Medicine; Rosiglitazone; Thiazolidinediones | 2021 |
Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Predictive Value of Tests; Prospective Studies; Risk Factors; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Vasodilator Agents | 2008 |
The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.
Topics: Aged; alpha-Macroglobulins; Alzheimer Disease; Apolipoproteins E; Biomarkers; Cognition; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Complement Factor H; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Humans; Male; Middle Aged; New Zealand; Nootropic Agents; Proteomics; Reproducibility of Results; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Time Factors; Treatment Outcome | 2008 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effects and Adverse Reactions; Edema; Female; Genotype; Humans; Hypoglycemic Agents; Indans; Intelligence Tests; Interview, Psychological; Male; Middle Aged; Nasopharyngitis; Piperidines; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Disease Progression; Double-Blind Method; Female; Fluorodeoxyglucose F18; Glucose; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Indans; Male; Middle Aged; Neuropsychological Tests; Piperidines; Rosiglitazone; Thiazolidinediones | 2011 |
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Cognition Disorders; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mental Recall; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Outcome Assessment, Health Care; Pilot Projects; PPAR gamma; Retention, Psychology; Rosiglitazone; Thiazolidinediones | 2005 |
26 other study(ies) available for rosiglitazone and Alzheimer Disease
| Article | Year |
|---|---|
Exploring the Neuroprotective Potential of Rosiglitazone Embedded Nanocarrier System on Streptozotocin Induced Mice Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Humans; Male; Neuroprotective Agents; Rosiglitazone; Streptozocin | 2021 |
Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARγ agonism in an Alzheimer's mouse model.
Topics: Aged; Alzheimer Disease; Animals; Cognition; Diabetes Mellitus, Type 2; Disease Models, Animal; Hippocampus; Humans; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; PPAR gamma; Proteomics; Rosiglitazone | 2021 |
Neuroprotective Efficacy of Co-Encapsulated Rosiglitazone and Vorinostat Nanoparticle on Streptozotocin Induced Mice Model of Alzheimer Disease.
Topics: Alzheimer Disease; Animals; Mice; Nanoparticles; PPAR gamma; Rosiglitazone; Streptozocin; Thiazolidinediones; Vorinostat | 2021 |
PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Animals; Axons; Dentate Gyrus; Female; Fibroblast Growth Factors; HEK293 Cells; Humans; Insulin Resistance; Male; Mice; Mice, Knockout; Mutation; Phosphorylation; PPAR gamma; Rosiglitazone; Sodium Channels; Thiazolidinediones | 2017 |
Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Topics: Alzheimer Disease; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Gene Expression Regulation; Glucose Tolerance Test; Humans; Insulin; Insulysin; Learning; Mice; Mice, Transgenic; PPAR gamma; Ribonucleotides; Rosiglitazone; Streptozocin; Thiazolidinediones | 2018 |
[Effects of curcumin on expression of PI3K and p-pI3K in hippocampus of AD mice].
Topics: Alzheimer Disease; Animals; Curcumin; Disease Models, Animal; Hippocampus; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Rosiglitazone; Thiazolidinediones | 2013 |
[Dynamic effect of curcumin on urine concentration of neuronal thread protein in AD mice].
Topics: Alzheimer Disease; Animals; Curcumin; Enzyme-Linked Immunosorbent Assay; Mice; Mice, Transgenic; Nerve Tissue Proteins; Rosiglitazone; Thiazolidinediones | 2013 |
PPARγ recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anilides; Animals; Cognition; Female; Hippocampus; Humans; Injections, Intraventricular; Male; MAP Kinase Signaling System; Memory; Mice; Mice, Inbred Strains; Mice, Transgenic; Middle Aged; Nootropic Agents; Phosphorylation; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2014 |
Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.
Topics: Alzheimer Disease; Animals; Body Weight; Brain; Disease Models, Animal; Exploratory Behavior; Female; Hypoglycemic Agents; Learning Disabilities; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neuroimmunomodulation; Neuroprotective Agents; Nootropic Agents; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rosiglitazone; Spatial Learning; tau Proteins; Thiazolidinediones | 2015 |
[Rosiglitazone improves learning and memory impairment of 3 x Tg mice].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Glycosylation; Learning; Memory; Memory Disorders; Mice; Mice, Transgenic; Neurofilament Proteins; Phosphorylation; Rosiglitazone; tau Proteins; Thiazolidinediones | 2014 |
Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARγ agonism.
Topics: Action Potentials; Alzheimer Disease; Animals; Cognition; Entorhinal Cortex; Male; Mice; Mice, Inbred C57BL; Neurons; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2015 |
Alzheimer's tests under fire.
Topics: Age of Onset; Alzheimer Disease; Apolipoprotein C-I; Apolipoproteins E; Clinical Trials as Topic; Genetic Predisposition to Disease; Genetic Testing; Genomics; Humans; Licensure; Pharmacogenetics; Philadelphia; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Down-Regulation; Hippocampus; Humans; Memory Disorders; Mice; Mice, Transgenic; PPAR gamma; Receptors, Glucocorticoid; Rosiglitazone; Thiazolidinediones | 2009 |
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cattle; Cells, Cultured; Dimerization; Hippocampus; Humans; Insulin; Neurons; Oxidative Stress; Protective Agents; Protein Binding; Receptor, Insulin; Rosiglitazone; Signal Transduction; Synapses; Thiazolidinediones | 2009 |
Targeting BuChE-inflammatory pathway by SK0506 to manage type 2 diabetes and Alzheimer disease.
Topics: Adipose Tissue; Alanine Transaminase; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Blood Glucose; Butyrylcholinesterase; Diabetes Mellitus, Type 2; Dietary Fats; Drugs, Chinese Herbal; Fatty Liver; Inflammation; Interleukin-6; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2009 |
Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Astrocytes; Brain; Disease Models, Animal; Inflammation; Lithium Compounds; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Nerve Degeneration; Nerve Tissue Proteins; Presenilin-1; Rosiglitazone; Signal Transduction; Thiazolidinediones; Wnt Proteins | 2010 |
Rosiglitazone effects to ameliorate Alzheimer's disease pathogenic features: insulin signaling and neurotrophic factors.
Topics: Alzheimer Disease; Animals; Brain; Humans; Insulin; Nerve Growth Factors; Neuroprotective Agents; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2009 |
Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; CD11b Antigen; CD36 Antigens; Cyclooxygenase 2; Cytokines; Gene Expression Regulation; Humans; Hypoglycemic Agents; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neuropsychological Tests; Peptide Fragments; Recognition, Psychology; Rosiglitazone; tau Proteins; Thiazolidinediones | 2010 |
Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Area Under Curve; Association Learning; Blood Glucose; Cognition; Disease Models, Animal; Hyperinsulinism; Hypoglycemic Agents; Insulin; Memory; Mice; Mice, Transgenic; Rosiglitazone; Thiazolidinediones | 2011 |
Rosiglitazone improves spatial memory and decreases insoluble Aβ(1-42) in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Female; Maze Learning; Memory; Mice; Neuroprotective Agents; Rosiglitazone; Thiazolidinediones | 2012 |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Argentina; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Progression; Female; Geriatric Assessment; Hippocampus; Humans; Hypoglycemic Agents; Insulin; Longitudinal Studies; Male; Neuropsychological Tests; Oxidative Stress; Pilot Projects; Psychiatric Status Rating Scales; Rosiglitazone; Severity of Illness Index; Thiazolidinediones | 2012 |
Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Line, Tumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Insulin; Mice; Neurons; Phosphorylation; PPAR gamma; Presenilin-1; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Sequence Deletion; Signal Transduction; tau Proteins; Thiazolidinediones | 2012 |
9th International Conference on AD and related disorders (ICAD).
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Donepezil; Humans; Hypoglycemic Agents; Indans; Mannich Bases; Nootropic Agents; Piperidines; Rosiglitazone; Thiazolidinediones | 2004 |
Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Disease Models, Animal; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Mice, Transgenic; Reference Values; Rosiglitazone; Stress, Physiological; Thiazolidinediones | 2004 |
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Behavior, Animal; Corticosterone; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Fibrinolytic Agents; In Situ Hybridization; Insulysin; Learning Disabilities; Male; Memory Disorders; Metyrapone; Mice; Mice, Transgenic; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone induces mitochondrial biogenesis in mouse brain.
Topics: Alzheimer Disease; Animals; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Brain; Cognition; DNA, Mitochondrial; ERRalpha Estrogen-Related Receptor; Frontal Lobe; Gene Expression Regulation; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Organelle Biogenesis; PPAR gamma; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2007 |